Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2016-11-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
七届十八次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board of 哈药集团股份有限公司 regarding adjustments to the company's restricted stock incentive plan. It details changes in the number of incentive recipients and shares granted, and confirms compliance with relevant laws and regulations. The document is an official announcement of a board or supervisory committee decision related to management and governance matters, specifically about stock incentive adjustments. It is not a full financial report, earnings release, or regulatory filing of financial results. It also does not fit into categories like director dealings or capital changes since it focuses on the supervisory board's resolution. Therefore, the best fitting category is Board/Management Information (MANG). The document length and content support this classification with high confidence.
2016-11-27 Chinese
上海荣正投资咨询有限公司关于哈药集团股份有限公司限制性股票激励计划首次授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a restricted stock incentive plan for 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It includes detailed explanations of the stock incentive plan, approval procedures, adjustments to the stock grant, and the advisor's verification opinions. The document is about a specific corporate action involving stock incentives and contains detailed financial and procedural information. It is not a general annual or quarterly report, nor is it a simple announcement or certification. It is a standalone advisory report related to a corporate financing/incentive activity. Given the nature of the content focusing on stock incentives and adjustments, it fits best under Capital/Financing Update (CAP). The document length is 4414 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is CAP with high confidence.
2016-11-27 Chinese
七届十八次监事会决议
Board/Management Information Classification · 95% confidence The document is a resolution from the Supervisory Board (监事会) of 哈药集团股份有限公司 regarding adjustments to a restricted stock incentive plan. It details the meeting date, attendees, voting results, and specific changes to the stock incentive allocations. There is no indication that this is a full financial report, audit report, or earnings release. It is not a shareholder meeting presentation or voting result announcement. The content focuses on management decisions related to stock incentives, which is a form of board/management information. The document length is short (810 characters), but it contains substantive content about management decisions rather than just an announcement or notice. Therefore, the best fitting category is Board/Management Information (MANG).
2016-11-27 Chinese
国浩律师（上海）事务所关于哈药集团股份有限公司股权激励计划授予限制性股票事项之法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's restricted stock incentive plan grant. It details approvals, authorizations, and legal compliance related to the stock incentive plan. There are no financial statements, earnings data, or management discussion of financial results. The document is a legal opinion on a specific corporate action (stock incentive plan) rather than a financial report or announcement of voting results. It is not a regulatory filing or announcement of a report publication. The content fits best under a legal proceedings or legal opinion category related to corporate governance and compliance. Given the available categories, the closest match is Legal Proceedings Report (LTR), as it involves legal opinions on corporate stock incentive matters.
2016-11-27 Chinese
关于分公司产品抽检不合格情况的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding a regulatory issue with a product from one of its subsidiaries, including details of administrative penalties and the company's response. It is not a financial report, earnings release, or management discussion. The document is relatively short (1171 characters) and focuses on regulatory and compliance matters related to product safety and administrative penalties. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-11-16 Chinese
关于哈药总厂大气污染物排放涉嫌超标的情况公告
Environmental & Social Information Classification · 95% confidence The document is a public announcement by the company's board regarding an environmental issue related to alleged excessive emissions of air pollutants by a subsidiary. It includes details about investigations by environmental authorities, company responses, and potential impacts on operations. The document is short (888 characters) and focuses on a specific regulatory and environmental matter rather than financial results or corporate governance changes. It does not contain financial statements, management discussion, or voting results. It is not a report publication announcement or certification. The content aligns with Environmental & Social Information (ESG) reporting, specifically addressing environmental compliance and pollution issues.
2016-11-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.